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Abstract
Background: Metastatic colorectal cancer (mCRC) with wild type 
expression of RAS and RAF genes can be treated with anti-epider-
mal growth factor receptor (EGFR) monoclonal antibodies, such as 
cetuximab, in combination with chemotherapy. Skin toxicity repre-
sents the most serious and frequent side effect in these patients. Skin 
manifestations occur in approximately 80% of patients. In this study, 
we investigated the consequences on body image and quality of life 
(QoL) of patients with severe skin toxicity.
Methods: One hundred patients were enrolled with mCRC. All pa-
tients signed informed consent and completed questionnaires to as-
sess QoL and body discomfort. Toxicity was assessed on Common 
Terminology Criteria for Adverse Events (CTCAEs).
Results: The greatest impact on QoL was represented by difficulties 
in managing skin rash-related side effects. Data showed a significant 
impact in psychological sphere and social relationships.
Conclusions: Skin side effects, particularly rash, influence QoL and 
social relationships, compromising therapeutic compliance.
Keywords: Quality of life; Cetuximab; Chemotherapy; Metastatic 
colorectal carcinoma; Metastases; Skin rash; Psychological reactions
Introduction
Metastatic colorectal cancer (mCRC) is the second cause of 
cancer death in Europe and the third most common cause of 
cancer mortality in USA. About 35% of patients with mCRC 
have clinically detectable liver metastases at diagnosis and ap-
proximately 45% develop metastases during disease [1]. The 
5-fluorouracil plus leucovorin became the standard of care of 
this disease, with median overall survival (OS) of 8 - 9 months. 
The addition of oxaliplatin and irinotecan, with FOLFOX- 
FOLFIRI regimens, gained 18 - 20 months [2] and the intro-
duction of new drugs into clinical practice has progressively 
improved survival in advanced disease, bringing median sur-
vival up to 24 months, and in some cases the drugs have al-
lowed to convert the disease from unresectable to resectable 
[2-4].
Furthermore, biological agents as epidermal growth factor 
receptor (EGFR) or vascular endothelial growth factor recep-
tor (VEGFR) inhibitors seem to offer further therapeutic op-
tions [5]. The monoclonal antibody cetuximab (Erbitux®) is 
the EGFR inhibitor most studied and approved by FDA for 
mCRC treatment with EGFR expression and without RAS 
gene mutations (Ras wild type) approved in first and later lines 
of treatment [6, 7].
Cetuximab has an important therapeutic effect on meta-
static disease, and improves survival curves and overall re-
sponse rate. In about 80% of patients, cetuximab causes dis-
figuring skin toxicity, mainly in the face and neck. The skin 
lesions begin as a diffuse facial erythema also in the neck, 
flaking, dry skin with diffuse and itchy folliculitis similar to 
acne, which evolves into pustules with formation of strongly 
adherent yellowish crusts [7-9].
The most commonly reported adverse event is acneiform 
rash, typically mild or severe in up to 18% of patients [10, 
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11]. Patients often experiment edema and erythema during first 
week of therapy following by papules, pustules and crusting. 
Paronychia and fissures are latter events.
The papules and pustules are often accompanied by tel-
angiectasias, with an image similar to that of rosacea. These 
acneiform eruptions are often associated with microbial in-
fections. In persistent lesions, the bacterial colonization with 
Staphylococcus aureus and/or detection of herpes simplex type 
I is not uncommon. In 15% of cases, skin manifestations can 
be so severe as to cause skin necrosis, nail changes (paronych-
ia) and inflammation with eyes redness, tearing and sensitivity 
to light with blurred vision [12].
Eczematization and bacterial overlap are complications 
that can occur in areas less resistant to infections; in these 
cases, the choice treatment is based on low-dose topical corti-
costeroids in combination with antibiotics.
The main pharmacological treatment is the oral or topi-
cal application of tetracycline family, such as doxycycline or 
minocycline, antibiotics or corticosteroid alone or in combina-
tion, accompanied by sun creams with protection factors [13].
Painful fissures were observed in fingers and toes, altera-
tions of the plate nail and paronychia, after 2 months of treat-
ment, as well as pyogenic granulomas [14, 15]. Most skin reac-
tions develop within first or third week of therapy. However, 
the presence and severity of rash is associated with better clini-
cal efficacy in patients being treated with EGFR inhibitors [16].
Furthermore, the reaction to treatment varies from indi-
vidual to individual and, depending on treatment type per-
formed, moreover, not all patients undergoing therapy show 
side effects [17].
In severe cases that clearly disfigure patients’ faces, treat-
ment discontinuation is necessary.
Skin lesions from cetuximab often disfigure patient’s face 
and physical appearance with a serious psychological impact 
that leads patient to withdraw the social, a similar impact such 
as alopecia or mutilation of surgical procedures such as mas-
tectomy or colectomy [18, 19]. A multidisciplinary approach, 
with a psycho-oncologist in team, is the best way to properly 
manage the patient with mCRC [20]. At least two-thirds of pa-
tients with mCRC suffer side effects associated with chemo-
therapy that cause distress, anxiety and depression. These side 
effects are a determining component in the experience of the 
disease that significantly compromise quality of life (QoL). 
In fact, most patients fear, not so much by the disease but by 
physical and psychological consequences to treatment [21]. 
There is a negative modification of image and self-concept, a 
fall in self-esteem, lifestyle, and affective and marital relation-
ships can be modified. The emotions that accompany this loss 
process range from shock to denial, from anger to fear, from 
bitterness to pain, to depression and despair [22].
Embarrassment and shame can be reflected in persecutory 
experiences such as feeling stigmatized and avoided. Advances 
in oncology research and new therapeutic strategies with chro-
nicization of oncological disease have made QoL of crucial 
importance in the patient’s survival. This aspect can influence 
psychological well-being of patient and care adherence [23]. 
Few studies assessed the psychological impact of disfiguring 
skin conditions in patients with mCRC and the extent to which 
the rash can affect the psychological well-being of patients 
with skin toxicity had a significant impact on distress [24].
In this study we hypothesized that skin reactions decrease 
QoL and have a great impact on psycho-social sphere. On 
these data, we conducted a study to evaluate the skin manifes-
tations induced by cetuximab and QoL of patients, evaluating 
whether these conditions can lead to impairment of the social 
sphere, as often happens in patients with alopecia. The aim of 
this study was to evaluate skin toxicity effects on the QoL and 
on the social sphere, of patients with colorectal cancer treated 
with cetuximab. In particular, we also assessed the impact of 
the rash on body image perception. The primary objective was 
to investigate the relationship between skin rash and QoL. The 
second objective was assessing whether QoL affects the psy-




All patients with mCRC who received cetuximab treatment 
in combination with chemotherapy, from April 2012 to June 
2019, were included in this study. The study was approved by 
IRB, written informed consent to participate was obtained by 
all participants. The study was conducted in accordance with 
the provisions of the Helsinki Declaration and good clinical 
practice guidelines. The following inclusion criteria were re-
quired: patient age > 18 years; mCRC; at least three cycles 
of cetuximab treatment plus chemotherapy in disease with 
expression of EGFR and without RAS gene mutations (wild 
type: WT); a performance status between 0 and 2 evaluated 
according to the criteria of the Eastern Cooperative Oncology 
Group (ECOG). Following a preliminary review to socio-de-
mographic format, subjects who did not have an adequate level 
of understanding of Italian language and those who had obvi-
ous psychiatric disorders (i.e., intellectual disabilities, serious 
psychotic symptoms) were excluded from the study, which 
prevented from understanding the research objectives and in-
vestigation applications. All participants were informed about 
the purpose of the study and signed the informed consent prior 
to evaluation. Those who agreed were asked to complete a 
protocol containing self-assessment measures with pencil and 
paper. The completion time was about 20 min. Self-evaluation 
was carried out at the health facility to ensure data confiden-
tiality. After randomization, patients were monitored for skin 
rash, adverse events, QoL and perception body image. The ref-
erence patient’s oncologist evaluated patients for the recording 
of adverse events according to Common Terminology Criteria 
for Adverse Events (CTCAEs) version 3.0 [25].
Instruments
Socio-demographic form
This module is specially designed to be used during adminis-
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tration, making it useful both for collection socio-demographic 
data and for understanding disease information. The socio-de-
mographic variables evaluated were: age, sex, place of birth, 
marital status, education, employment, type of treatment and 
therapies.
European Organization for Research and Treatment of Can-
cer (EORTC-C30)
The EORTC QLQ-C30 [26-28] is a questionnaire validated 
by EORTC Group. The questionnaire consists of 30 items 
on a four-point scale Likert (1 = “no“; 4 = “very much”) that 
evaluate QoL of cancer patients in the last 7 days. Five items 
evaluate general function scale (physical, role-playing, emo-
tional, cognitive and social), three items evaluate symptom 
scales (fatigue, nausea/vomiting and pain), one item evaluates 
the global health/quality of life scale, and six items evaluate 
physical questions (breathing, insomnia, anorexia, constipa-
tion, diarrhea and economic impact of the disease). All scales 
and single element sizes vary in score from 0 to 100. A high 
score represents a higher level of response. Thus, a high score 
for a functional scale represents a high/healthy level of func-
tioning, a high score for the overall health status/QoL, but a 
high score for a symptom physical scale represents a high level 
of problems.
Body uneasiness test (BUT)
BUT [29] is self-report psychometric questionnaire for clini-
cal evaluation of discomfort related to body image. The test 
consists of 71 items with multiple choice responses and is di-
vided into two parts. The first part (BUT a) consists of 34 items 
whose overall average score identifies the degree of severity 
related to an individual’s body image (Global Severity Index 
(GSI)). It consists of five areas: weight phobia (WP), body im-
age concerns (BIC), prevention (A), compulsive self-monitor-
ing (CSM), and depersonalization (D). The second part (BUT 
b) is composed of 37 items that list parts and functions of the 
body. Gravity is expressed as a scale from 0 to 5, where 0 cor-
responds to the absence of problems in that sector and 5 to the 
maximum gravity. The judgement of gravity is expressed in 
this case on a scale from 0 to 37, where 0 corresponds to the 
absence of the symptom and 37 to the maximum discomfort of 
the body. BUT test showed good internal consistency with a 
Cronbach α value of 0.87.
Statistical analysis
After checking univariate normality of distributions using 
asymmetry and kurtosis indices, we tested multivariate nor-
mality between variables using Mardia coefficient. The de-
scriptive statistics (mean, standard deviation) were calculated 
and correlations between the variables were calculated. The 
reliability of each scale was assessed using Cronbach inter-
nal consistency index. The descriptive statistics were used to 
summarize the demographic and study variables. Examining 
the differences between the participants’ average scores and 
value test (cut-off), t-tests of a sample were conducted. The 
t-test was used to compare the mean values of the continuous 
variables for both BUT and EORTC-C30. A P value of 0.05 
was considered statistically significant. The correlation sig-
nificance between the variables was assessed by Chi-square 
(χ2) test, Pearson’s correlation coefficient. All analyses were 
performed using the statistical software SPSS (Statistical Sys-




A total of 100 patients were enrolled in the study. The nor-
mality index verified through univariate indices of asymmetry 
and kurtosis with 1 acceptance threshold. No variables showed 
normal violations. The multivariate index of Mardia and kurto-
sis calculated on variables was 311, below the critical limit of 
399. Patients characteristics with mCRC included in the study 
are shown in Table 1. The 66% of participants were women 
and 34% were men. The participants average age was 58 years 
(range 35 - 75). All participants were Italian. Of the samples, 
15% were single, 76% were married, 4% were separated/ di-
Table 1.  Socio-Demographic Data (N = 100)
Age (range) 58 (35 - 75)
Sex
  Females 66 (66%)
  Males 34 (34%)
ECOG performance status
  0 14 (14%)
  1 37 (37%)
  2 48 (49%)
First line of chemotherapy
  Yes 51 (51%)
  No 49 (49%)
Civil status
  Single 15 (15%)
  Married 76 (76%)
  Widowed 5 (5%)
  Separated/divorced 4 (4%)
Education level
  Primary school 2 (2%)
  Secondary school 8 (8%)
  High school 53 (53%)
  Graduated 37 (37%)
ECGO: Eastern Cooperative Oncology Group.
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vorced and 5% were widowed. Most samples had a higher 
level of education (90%) (Table 1).
Skin toxicity
The skin toxicity was assessed at baseline (before starting 
antineoplastic treatment) and at every subsequent visit, using 
CTCAE system. The assessment of several aspects of target-
ed therapy-related adverse events was conducted, using five 
grades of severity, and the severity is established on the basis 
of clinical presentation and the reported distress of the patient 
(such as pruritus and burning). The data showed that none of 
patients (0%) was grade 0, 10 patients (10%) were grade 1, 
35 patients (35%) were grade 2, 47 patients (47%) were grade 
3, and eight patients (8%) were grade 4 (Table 2). A signifi-
cant correlation was found between skin rash and overall QoL, 
with a Pearson correlation coefficient of -0.65 (P = 0.0001). 
The major effects of dermal toxicity on QoL were physical 
symptoms (e.g., skin itching), while emotional disorders were 
reported less frequently such as associated to impairment in 
QoL (Table 3).
QoL
In general, 78% of patients interviewed report a good QoL, as 
shown in Table 4. The data of questionnaire report a greater 
impact on daily routine, with consequences in relationships 
and social roles (low scores in the social functioning dimen-
sion of EORTC QLQ-C30 scale). The patients express nega-
tive feelings such as anxiety, fear and suffering, consistent 
with an emotional malfunction within the dimension emo-
tional functioning scale of EORTC QLQ-C30. In particular, 
patients who have performed multiple treatment lines show 
poor relationships in family and with friends (low scores in 
the social functioning scales of EORTC QLQ-C30). The 87% 
of samples interviewed report insomnia. The most difficult 
common concerns related to physical well-being were pain-
ful, irritating and irritated skin, itching and increased hair 
growth. A variety of symptoms were seen, such as itching, 
burning/tingling. These symptoms interfered with sleep, abil-
ity to work, their daily activities and their hobbies. In general, 
QoL decreased during the study course. This significant drop 
in QoL underlines the continue need looking for interventions 
that may mitigate this skin-related toxicity in patients receiv-
ing EGFR inhibitors.
Psycho-social implications
The psycho-social dimensions assessed by BUT questionnaire 
show higher scores for body image with consequence of avoid-
ance behavior of social relationships, leading the subject to 
isolate themselves (Table 5). Patients reported embarrassment 
and their skin toxicity interfered with their ability to show 
affection. Most patients have felt a sense of loneliness, with 
difficulty leaving home and delegated their family member to 
communicate with friends. Of patients, 52% responded that 
they had avoided going out, experienced concern, frustration 
Table 2.  Skin Toxicity Using CTCAE (N = 100)
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Skin rash 0 (0%) 10 (10%) 35 (35%) 47 (47%) 8 (8%)
CTCAE: Common Terminology Criteria for Adverse Event.
Table 3.  Pearson’s Correlation of Skin Rash and QoL in Pa-
tients Receiving Cetuximab (N = 100)
Skin rash QoL
Skin rash 1 -0.65*
QoL -0.65* 1
*P < 0.01. QoL: quality of life.
Table 4.  Average Scores and Standard Deviation of Question-
naire EORTC QLQ-C30 (N = 100)
QoL Average (SD)
Functional scale
  Physical function 77.6 (16.5)
  Functional role 65.8 (29.4)
  Emotional state 81.6 (23.1)
  Cognitive function 88.4 (26.3)
  Social function 45.3 (21.7)
  Global health/QoL 55.9 (18.5)
  Insomnia 46.9 (18.7)
Symptom scale
  Fatigue 59.4 (26.2)
  Pain 13.2 (25.1)
  Dyspnea 11.5 (21.7)
  Constipation 19.4 (26.1)
  Appetite loss 28.7 (29.2)
  Diarrhea 22.8 (29.7)
  Nausea, vomiting 41.3 (22.6)
  Financial difficulties 14.7 (19.3)
EORTC QLQ-C30: European Organization for Research and Treat-
ment of Cancer; QoL: quality of life; SD: standard deviation.
Table 5.  Average Score and Standard Deviation of BUT Test 
(N = 100)
Average (SD)
Weight phobia 9.7 (7.4)
Concern for the image of the body 18.2 (8.5)
Avoidance behavior 16.3 (7.8)
Compulsive control of image 6.6 (16.4)
Depersonalization 9.2 (11.17)
BUT: body uneasiness test; SD: standard deviation.
Articles © The authors   |   Journal compilation © World J Oncol and Elmer Press Inc™   |   www.wjon.org108
Skin Rash in Metastatic Colorectal Cancer World J Oncol. 2021;12(4):104-110
and depression, due to their dermatological rash. Data suggest 
that skin toxicity associated with EGFR inhibitors had a pro-
found impact on physical function, emotional and social of the 
patient also interfering with treatment compliance. Fear, frus-
tration and depression were related to their skin symptoms and 
concerned about the scarring from skin toxicity. High score 
was found in social discomfort dimension with isolation be-
haviors also for work, related to concerns about how others 
would react.
Discussion
EGFR antibodies, associated with chemotherapy, prolong 
survival in mCRC. However, often in patients, it develops 
severe skin toxicity. This occurs in about 80% of treated pa-
tients, negatively affecting their QoL and their resistance to 
disease [15, 16]. The psycho-educational approach, with cor-
rect information on the side effects and their possible treat-
ment, could play a decisive role in therapeutic compliance and 
psychological well-being of patient [30]. In this study, rash 
had a negative impact on QoL and body perception. Social 
relationships were avoided through embarrassment, unease 
and body shaming. The results confirmed the correlation be-
tween skin manifestations and compromised QoL. Therefore, 
QoL and perception of body image influence the acceptance 
of the diagnosis, better therapeutic compliance, disease adap-
tation and consequently a greater acceptance of side effects 
[16-31]. From data of our study, patients did not believe skin 
toxicity as a priority during their treatment, but their manage-
ment caused distress. Both during and after treatment, the 
attention to the side effects of chemotherapy, in particular 
management of the skin rash, is a priority in mCRC patients. 
The main objective of this research was therefore to evaluate 
psychological well-being, implement effective interventions 
in order to reduce physical and psychological discomfort and 
motivate patients to tolerate symptoms because the toxicity 
is often index to treatment response. In fact, when the follow-
up shows a good response to treatment, the patient accepts 
the skin toxicity with less distress. The neoplastic disease is 
characterized as a complex pathology which requires a mul-
tidisciplinary and integrated approach to the patient that also 
involves the psycho-oncologist, which is able to evaluate its 
different aspects and its different implications, not only from 
a physical but also psychological point of view [32-34]. The 
psycho-oncologist is of fundamental importance exactly in 
patient’s subjective perception and coping strategies to face 
up the disease. The psychological intervention involves tak-
ing care of the patient through weekly interviews and the ad-
ministration of psychometric tools, promoting adaptive cop-
ing strategies that allow for patient not to break down and 
surrender to the first symptoms of rash. Although significant 
QoL alteration has been observed in patients receiving EGFR 
inhibitors, skin rash must be addressed in supportive inter-
ventions in routine management before this hinders treat-
ment. Psycho-oncological work should focus on minimizing 
distress and developing active coping strategies, motivating 
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